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Abstract
Herpes simplex virus type 1 (HSV-1) requires the activities of cellular kinases for efficient
replication. The host kinase, CK2, has been shown or is predicted to modify several HSV-1
proteins and has been proposed to affect one or more steps in the viral lifecycle. Furthermore,
potential cellular and viral substrates of CK2 are involved in antiviral pathways and viral counter-
defenses, respectively, suggesting that CK2 regulates these processes. Consequently, we tested
whether pharmacological inhibitors of CK2 impaired HSV-1 replication, either alone or in
combination with the cellular antiviral factor, interferon-β (IFN-β). Our results indicate that the
use of CK2 inhibitors results in a minor reduction in HSV-1 replication but enhanced the
inhibitory effect of IFN-β on replication. This effect was dependent on the HSV-1 E3 ubiquitin
ligase, infected cell protein 0 (ICP0), which impairs several host antiviral responses, including that
produced by IFN-β. Inhibitors of CK2 did not, however, impede the ability of ICP0 to induce the
degradation of two cellular targets: the promyelocyticleukemia protein (PML) and the DNA-
dependent protein kinase catalytic subunit (DNA-PKcs). Notably, this effect was only apparent for
HSV-1, as the CK2 inhibitors did not enhance the antiviral effect of IFN-β on either vesicular
stomatitis virus or adenovirus type 5. Thus, our data suggest that the activity of CK2 is required
for an early function during viral infection that assists the growth of HSV-1 in IFN-β-treated cells.
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1. Introduction
HSV-1 is a widespread human pathogen, infection by which can cause facial ulcerations,
commonly known as cold sores, and in more extreme cases herpes stromal keratitis and
encephalitis (Fields et al., 2007). HSV-1 has a biphasic lifecycle consisting of a lytic state
that occurs primarily in the oral-facial epithelium and a latent state, where the viral genome
establishes a quiescent infection in the neurons of the trigeminal ganglion (Fields et al.,
2007). During the lytic cycle, the viral proteins are produced in a temporal cascade
consisting of immediate-early (IE), early (E), and late (L) phases, with the expression of
each phase dependent upon the preceding class (Honess and Roizman, 1974). The successful
establishment of infection and progression through the lytic phase of replication requires the
coordinated effort of many viral and cellular factors to stimulate viral gene expression to
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ultimately produce infectious progeny virus (Honess and Roizman, 1974). A common theme
in the regulation of these proteins is their post-translational modification by
phosphorylation. AlthoughHSV-1 encodes at least two of its own protein-directed kinases –
UL13 and US3 –, efficient replication appears to require several cellular kinases, most
notably certain cyclin-dependent kinases (Schang et al., 1998) and stress activated protein
kinases (Karaca et al., 2004). HSV-1′s requirement for cellular kinases makes the use of
pharmacological inhibitors against these kinases a potential avenue for anti-herpetic
treatments.
CK2, formerly called casein kinase II, is a ubiquitously expressed and highly conserved
cellular serine/threonine kinase that targets a S/T-x-x-D/E motif. With over300 known
cellular substrates, CK2 is implicated as functioning in a wide variety of cellular processes,
including apoptosis, proliferation, and transcription, where its activity can be broadly
described as pro-cell survival and pro-cell growth (reviewed in (Meggio and Pinna, 2003)).
While there are many cellular factors implicated in the regulation of its activity, CK2 is
typically described as constitutively expressed and active (Allende and Allende, 1995;
Montenarh, 2010); however, this regulation is important as CK2 is frequently found to be
overactive in a number of pathogenic conditions, including tumorigenesis (Ahmad et al.,
2005).
In addition to its cellular targets, proteins from several different viruses have been reported
to serve as CK2 substrates. In the case of HSV-1, proteins from all three kinetic classes,
including the IE proteins ICP0 (Davido et al., 2005), ICP4 (Bates and DeLuca, 1998), ICP27
(Zhi and Sandri-Goldin, 1999); the E protein ICP6 (Conner, 1999); and the L proteins VP1/2
(Morrison et al., 1998), VP13/14 (Morrison et al., 1998), VP16 (O’Reilly et al., 1997), VP22
(Elliott et al., 1999), and gE (Wisner et al., 2000) contain CK2 consensus phosphorylation
sites, and in several instances mutation of these sites compromises viral replication (Xia et
al., 1996; Davido et al., 2005; Potel and Elliott, 2005; Rojas et al., 2010). Perhaps owing to
the potential importance of CK2 inHSV-1 replication, CK2 is the only cellular kinase, to
date, that has been shown to be packaged in the tegument of the assembled virion (Loret et
al., 2008). Additionally, HSV-1 has been reported to stimulate CK2 activity through the IE
protein ICP27, which physically interacts and relocalizes CK2 at early times during
infection (Koffa et al., 2003).Of these viral targets, both ICP0 and ICP27 are involved in
counteracting the repressive effects of the cellular antiviral pathway known as the interferon
(IFN) response. The IFN response is triggered by viral infection and results in the
upregulation of a number of cellular factors that collectively serve to impede viral
replication (Haller et al., 2006). ICP0 is an E3 ubiquitin ligase that promotes viral gene
expression and contributes to a successful initiation of infection by inducing the degradation
of a number of cellular targets, including several that are upregulated by IFNs (Chelbi-Alix
and de Thé, 1999; Parkinson et al., 1999; Lomonte et al., 2001; Everett et al., 2006; Lilley et
al., 2010). ICP27 is a multifunctional mRNA/protein nuclear import/export shuttling factor
and regulatory protein that promotes viral mRNA translation and inhibits cellular protein
(Sandri-Goldin, 2008). While this implicates CK2 playing a role in the lifecycle of HSV-1,
the impact of inhibiting or removal of CK2 activity on HSV-1 replication has remained
largely unexplored.
Previous studies examining the role of CK2 during HSV-1 infection were unable to assess
the effect of CK2 on replication due to limitations of the inhibitors available at the time. For
example, at the concentrations necessary to inhibit CK2, a commonly used CK2 inhibitor,
5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB), also blocks the activity of CDK9
(Koffa et al., 2003; Wang and Fischer, 2008). In this study, we have taken advantage of
recently developed compounds that are more selective in their inhibitory properties. Our
results indicate that CK2 inhibitors have a minor impact on HSV-1 replication in cultured
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human fibroblasts; however, the use of CK2 inhibitors compromises the ability of the virus
to replicate in cells pretreated with the type I interferon, IFN-β, in a manner that was only
observed with HSV-1.
2. Materials and Methods
2.1 Cell and viruses
Human embryonic lung (HEL) cells were obtained from the American Type Culture
Collection (CCL-137) and grown in Minimum Essential Medium Eagle’s Alpha
Modification (αMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-
glutamine, 10 U/mL penicillin, and 10 U/mL streptomycin. Vero cells and L7 cells, which
are Vero cells that contain the ICP0 gene (Samaniego et al., 1997), were grown in
Dulbecco’s modified Eagle’s medium supplemented with 5% FBS, 2 mM L-glutamine, 10
U/mL penicillin, and 10 U/mL streptomycin. KOS (Smith, 1964) is the wild type HSV-1
strain used in these studies. 7134 is an ICP0-null mutant in which the ICP0open reading
frame is replaced by the E. colilacZ gene (Cai and Schaffer, 1989). KOS and 7134 viral
stocks were prepared in Vero cells and titered on either Vero (for KOS) or L7 cells (for
7134) as previously described (Schaffer et al., 1973; Davido et al., 2005). Adenovirus 5
(Ad5) was purchased from the American Type Culture Collection (VR-5) and propagated
and titered on HEK-293 cells (Halford et al., 2001). The vesicular stomatitis virus
recombinant, VSV-eGFP (Das et al., 2006), which encodes the enhanced green fluorescent
protein gene inserted between the G and L genes, was a gift from Dr. AsitPattnaik and was
propagated and titered on Vero cells.
2.2 Reagents
The CK2 inhibitors4,5,6,7-tetrabromo-1H-benzotriazole (TBB) and 2-
dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT) were purchased from EMD
Chemicals and 2-(4,5,6,7-tetrabromo-2-(dimethylamino)-1H-benzo[d]imidazol-1-yl)acetic
acid (TMCB) from Ascent Scientific. All CK2 inhibitors were constituted in DMSO
(Fischer Scientific). TBB and TMCB were used at 50 μM and DMAT at 20 μM.
Recombinant human IFN-β was purchased from R&D Systems.
2.3 Viral plaque reduction assays
For HSV-1 plaque reduction assays, HEL cells were plated in 24-well plates. Upon reaching
70% confluency, cells were either mock treated or treated with a given concentration of
IFN-β. After 16 hours of IFN-treatment, cells were prewashed with either medium; medium
plus IFN-β; medium plus DMSO (as vehicle control), TBB, or TMCB; or medium plus IFN-
β and either vehicle or CK2 inhibitor. Cells were then infected with 10-fold serial dilutions
of HSV-1 in the aforementioned media. At 1 hour post infection (hpi), the cells were
overlaid with cell culture medium containing 0.5% methylcellulose and the appropriate
compounds. At 3 days post infection (dpi), monolayers were fixed with 3.7% formaldehyde,
probed with a horseradish peroxidase (HRP)-conjugated anti-HSV antibody (Dako), and the
resulting plaques were visualized with Vector Red substrate (Vector Labs). Plaque areas
were determined by capturing images of immunohistochemically stained plates with a
flatbed scanner (Canon), measuring the number of pixels that corresponded to an individual
plaque in Adobe Photoshop. Pixel values were converted to mm2 by dividing by the number
of pixels per inch for the image. Four to twenty plaques were measured per treatment from
two experiments.
For Ad5 plaque reduction assays, HEL cells were treated and infected as described for the
HSV- 1 plaque assays. At 5 dpi, cells were washed once with PBS, fixed for 5 minutes with
5% formaldehyde in PBS, washed three times with PBS, permeabilized at 4°C for 15
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minutes with 0.5% NP-40 in PBS, and washed an additional three times with PBS. Ad5
infected cells were detected by probing the cells with a FITC-conjugated anti-adenovirus
antibody (B65140F, Meridian Life Science)diluted in PBS and the resulting plaques and
cells were visualized and counted by fluorescence microscopy (Nikon).
For VSV-eGFP reduction assays, HEL cells were again treated and infected as described for
HSV-1 plaque assays with the exceptions that the cells were treated with 10 U/mL of IFN-β,
and the monolayers were overlaid with 2% methylcellulose. At 1 dpi, the cells were washed
three times with PBS and fixed with 3.7% formaldehyde in PBS for 5 minutes at room
temperature. Plaques were detected and counted by fluorescence microscopy (Nikon).
2.4 Viral yield assays
HEL cells were plated at 1 × 105 cells per well in 12-well plates and one day later were
either mock treated or treated with IFN-β. 16 hours later, cells were pre washed as described
above and subsequently infected for 1 h in the presence of the appropriate compounds with
either KOS or 7134 at a multiplicity of infection of 1. After 1 h the cells were overlaid with
cell medium containing the previously described compounds. At 24 hpi, cells were
harvested, and viral titers were determined on Vero or L7 cells for KOS or 7134,
respectively.
2.5 Western blots
HEL cells were plated, treated, and infected as described for HSV-1 yield assays. 12 and
24hpi, cells were washed once with PBS and then scraped into boiling Laemmliloading
buffer (Laemmli, 1970)containing 1 μg/mL leupeptin, 1 μg/mL aprotinin, 1
mMphenylmethanesulfonylfluoride, 10 mM sodium vanadate, 50 mM sodium fluoride, and
20 mM N-ethylmalemide. 10% of each sample was resolved on a 4–12% Bis-tris
polyacrylamide gel, transferred to nitrocellulose, blocked at room temperature for 1 h with
2% nonfat dry milk in Tris-buffered saline with 0.1% Tween 20 (TBS-T), and probed
overnight at 4°C with antibodies directed against either ICP4 (H1A021, EastCoast), UL42
(mAB3678, Millipore), PML (A301-167A, Bethyl Laboratories), or β-actin ((I-19)-R, Santa
Cruz Biotechnology). Membranes were then washed three times with TBS-T and probed at
room temperature with either goat-anti-mouse IgG or goat-anti-rabbit IgG conjugated to
HRP (Jackson Immunoresearch). Membranes were again washed with TBS-T and developed
with chemiluminescent substrate (Femto ECL, Pierce Laboratories). Some membranes were
stripped by incubation in 2% SDS, 100 mM β-mercaptoethanol, 62.5 mMTris-HCl (pH 6.7)
at 55°C for 30 minutes. These membranes were thoroughly washed with TBS-T, blocked at
room temperature for 1 h with 2% milk/TBS-T, and probed overnight at 4°C with antibodies
directed against either ICP0 (sc-53070, Santa Cruz Biotechnology) or VP5 (ab6508,
Abcam). The membranes were then washed, probed with a secondary HRP-conjugated
antibody, and developed as before. Chemiluminescence was detected using an Image Station
4000R (Kodak) and Care stream Molecular Imaging software. Images were assembled using
Photoshop and Illustrator (Adobe Systems) and band intensities were measured by
densitometry analyses using ImageJ.
2.6 Immunofluorescence
HEL cells were plated at 1 × 105 cells per well in collagen-coated glass bottom 24-well
plates, treated, and infected as described above for the HSV-1 yield assays. At 12 hpi, the
cells were fixed and permeabilized as described above in the Ad5 plaque reduction assays.
Samples were blocked with 1% BSA, 5% FCS, and 1% goat serum in PBS for 1 h at room
temperature. Cells were then probed with antibodies against ICP0 (sc-53070), PML
(A301-167A), and DNA-PKcs (sc-5282, Santa Cruz Biotechnology) for 1 h in blocking
solution at 37°C. Monolayers were washed with PBS and probed with goat-anti-mouse
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immunoglobin (IgG) 2b Dylight 488 (Jackson Immunology), goat-anti-rabbit IgGAlexa 405
(Molecular Probes), and goat-anti-mouse IgG1a Dylight 594 (Jackson Immunoresearch) to
detect ICP0, PML, and DNA-PKcs, respectively. Proteins were viewed by confocal
fluorescent microscopy (Olympus) and captured with a digital camera (Hamamatsu). Images
were assembled using Photoshop and Illustrator (Adobe Systems).
3. Results
3.1 CK2 inhibitors reduce the plating efficiency and plaquing of HSV-1 in IFN-β-treated
cells
We initially sought to determine the requirement for CK2 activity during HSV-1 replication.
To this end, we employed plaque reduction assays to test the effect that two specific CK2
inhibitors, TBB (IC50 = 0.15 μM) and TMCB (IC50 = 0.50 μM) (Pagano et al., 2008), both
of which block the active site of CK2, have on the plating efficiency and spread of HSV-1 in
HEL cells. Additionally, because cellular factors responsible for the innate antiviral response
(e.g., IFN) and the viral factors that counteract this response are either known to be or are
potential CK2 substrates, we also examined how these inhibitors affected the ability of
HSV-1 to plaque in the presence of a type 1 interferon, IFN-β. HEL cells were untreated or
pretreated with 1000 U/mL of IFN-β for 16 hours and then infected with serial diluted
HSV-1 in the presence of the compounds as listed in Table 1. In these and subsequent
assays, TBB was used at 50 μM as previously described (Scaglioni et al., 2006), while a
preliminary dose response curve suggested that the same concentration was appropriate for
TMCB (data not shown); DMSO was used at 0.5% v/v as a vehicle control. As seen in Table
1, the use of each CK2 inhibitor alone resulted in only a modest reduction in plaque size
(3.9- and 1.4-fold decrease for TBB and TMCB, respectively) and plating efficiency of
HSV-1 (0 and 2-fold decrease for TBB and TMCB, respectively) compared to the untreated
samples. As expected, IFN-β reduced plaque size and plating efficiency 26- and 25-fold,
respectively. When DMSO was added to IFN-β, it had a slight effect on plaque size (1.8-
fold decrease versus IFN-β alone), and a negligible impact on plating efficiency. However,
the combination of IFN-β and either CK2 inhibitor further reduced viral plaque size and
plating efficiency (3.5- and 2.8-fold for TBB, and 2.6- and 2.1-fold for TMCB,
respectively), compared to IFN-β-treated cells. These results were further confirmed when
we used a third CK2 inhibitor, DMAT (data not shown). We then tested whether these
inhibitors would also enhance the IFN-sensitivity in cells treated with a suboptimal
concentration (50 U/mL) of IFN-β. This reduced amount of IFN, in either media alone or
with DMSO, indeed proved to be less effective at reducing either plaque size (~5-fold) or
plating efficiency (4-fold). Again, we found that both inhibitors, in combination with IFN-β,
reduced the plating efficiency of HSV-1 (9- and 7-fold) and both decreased viralplaque size
(42.1- and 10.3-fold for TBB and TMCB, respectively) beyond that of IFN alone. These
decreases in viral replication were not due to a loss of cell viability, as treatment with IFN,
CK2 inhibitor, or a combination of IFN and inhibitor did not increase in cell death as
measured by trypan blue exclusion assay. Specifically, by three days post treatment, there
was a 15% loss in cell viability with mock-treated HEL, where all other treatment groups
had a similar (9–23%)loss in cell viability.
3.2 CK2 inhibitors reduce viral replication in IFN-β-treated cells in an ICP0-dependent
manner
We then examined whether the decreases in the plating efficiencies and plaque sizes
observed in Table 1 correlated with reductions in productive infection. In addition, we
included an ICP0-null mutant virus in these experiments because ICP0 has been shown to
assist HSV-1 in counteracting the IFN response (Mossman et al., 2000; Eidson et al., 2002;
Härle et al., 2002)and is a potential target of CK2 phosphorylation (Davido et al., 2005).
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Cells were pretreated with IFN-β and infected with 1 plaque forming unit (PFU) per cell of
either HSV-1 or an ICP0-null mutant virus in the presence of the reagents. As shown in
Figure 1, IFN-β treatment alone reduced the replication of HSV-1 by 28-fold and the ICP0-
null mutant by 212-fold, while treatment with DMSO or either CK2 inhibitor resulted in a
minor (~2 fold) reduction in replication. However, when the inhibitors were used in
conjunction with IFN-β, the replication of HSV-1 was decreased by a factor of 145-fold with
TBB and 69-fold with TMCB where as the ICP0-null mutant was reduced by a factor of
182-fold with TBB and 141-fold with TMCB. These results demonstrate that CK2 inhibitors
increase the antiviral effects of IFN-β on HSV-1 productive infection and suggest the
enhancement by the CK2 inhibitors may be related to the anti-IFN-mediated activity of
ICP0.
3.3 CK2 inhibitors in conjunction with IFN-β decrease the levels of early and late proteins
To identify the point(s) in the viral lifecycle impaired by the combination of CK2 inhibitor
and IFN-β, we analyzed the accumulation of specific viral proteins by western blot analysis.
HEL cells were again pretreated with IFN-β and infected with HSV-1at 1 PFU per cell in the
presence of the reagents. At 12 and 24 hpi, Western blots were used to assess the levels of
the viral proteins ICP4, UL42, and VP5 as representative examples of IE, E, and Lproteins,
respectively. The results in Figure 2 show that, as expected, the CK2 inhibitors alone had
little effect on the accumulation of the viral proteins examined. IFN treatment delayed viral
protein expression, with an overall reduction for all 3 kinetic classes tested. While the
combination of IFN-β and CK2 inhibitor did not decrease ICP4 levels more than for IFN-β
alone, there was a decline in UL42 (>100-fold for TBB and TMCB) and VP5 (>9-fold for
TBB and TMCB) levels at 24 hpi. These results indicate that the use of the CK2 inhibitors
impairs the function of at least one IE protein to activate the synthesis of E and L proteins.
3.4 CK2 inhibitors do not affect the stability of ICP0-directed targets of degradation
Since the viral replication assays indicated that the CK2 inhibitors did not increase the IFN
sensitivity of an ICP0-null mutant, we assayed the impact that the CK2 inhibitors had on the
E3 ubiquitin ligase activity of ICP0. ICP0, thought itsE3 ubiquitin ligase activity, appears to
induce the proteosomal-dependent degradation of a number of cellular targets in order to
assist HSV-1 in overcoming cellular antiviral responses. As a result, we examined whether
the CK2 inhibitors impaired ICP0’s ability to induce the loss of two cellular targets, PML
and DNA-PKcs. HEL cells were pretreated with IFN-β and infected with HSV-1 in the
presence of CK2 inhibitors as described above. At 12 hpi, the cells were assayed for the
presence of ICP0, PML, and DNA-PKcs by immunofluorescence; at 12 and 24 hpi, cell
lysates were analyzed for PML and ICP0 levels by western blot. As shown in Figure 3,
while the use of either CK2 inhibitor, IFN-β, or the combination of CK2 inhibitor and IFN-β
decreased the number of ICP0-positive cells, a majority of cells that were positive for ICP0
either showed a decrease or loss of DNA-PKcs and PML, irrespective of treatment. When
we examined PML levels by western blot (Figure 4), however, it appeared that treatment
with TBB alone, in the absence of HSV-1, resulted in a slight stabilization of PML at 12 hpi,
and at 24 hpi when TBB was used with IFN-β in HSV-1 infected cells. While this might
indicate that CK2 is involved in PML degradation, it is also likely that PML levels were
higher due to a smaller proportion of cells expressing ICP0 (Figure 3). These results suggest
that the CK2 inhibitors do not compromise the E3 ubiquitin ligase activity of ICP0, or at
least the ability of ICP0 to induce the degradation of two of its targets.
3.5 The enhanced effect of CK2 inhibitors on IFN is observed with HSV-1 but not VSV and
Ad5
Given our results, there are two possibilities to explain how the use of CK2 inhibitors
increase the sensitivity of HSV-1 to an IFN-β-induced antiviral response: CK2 negatively
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regulates one or more cellular components of the IFN response that repress HSV-1
replication and thus the inhibitors increase the overall potency of IFN-β, or CK2 alters the
activities of one or more viral components that impairs the ability of IFN to restrict HSV-1
replication. To test these possibilities, we examined the effect that the CK2 inhibitors had on
the plating efficiency of two other viruses, VSV and Ad5. VSV and Ad5 were chosen for
these studies as they represent viruses that are genetically distinct from HSV-1 and are either
very sensitive to the effects of IFN (for VSV) or show high levels of IFN resistance (for
Ad5) (Anderson and Fennie, 1987). HEL cells were pretreated with IFN-β for 16 h and
infected with 10-fold serial dilutions of either Ad5 or the VSV recombinant, VSV-eGFP, as
described for HSV-1. At 1 dpi, VSV-eGFP-infected monolayers were fixed and GFP-
positive plaques counted; Ad5-infected monolayers were fixed at 5 dpi, stained with an
antibody directed against adenovirus, and plaques visualized by immunofluorescence. As
shown in Table 2, VSV replication was highly impaired by pretreatment with IFN, whereas
Ad5 was highly resistant, as expected. Similar to HSV-1, both of the CK2-inhibitors had
little to no effect on either VSV or Ad5 replication; however, unlike HSV-1, neither
inhibitor increased the IFN-sensitivity of VSV or Ad5. These data suggest that the activity
of CK2 is necessary for the ability of HSV-1 to diminish the effects of IFN on replication,
that this mechanism is specific to HSV-1, and that, at least in HEL cells, CK2 activity is not
required for the plaquing of either VSV or Ad5 regardless of the IFN response.
4. Discussion
HSV-1 requires the activity of a number of both viral and cellular kinases for efficient viral
replication. Because several of the potential viral CK2 substrates are involved in overcoming
cellular intrinsic and innate antiviral defenses and a number of those defenses are themselves
CK2 phosphorylation substrates (Zhi and Sandri-Goldin, 1999; Briggs et al., 2001; Davido
et al., 2005; Scaglioni et al., 2006; Sun et al., 2011), we investigated the effect that CK2
inhibitors have on HSV-1 replication in cells treated with the type I interferon, IFN-β.
Surprisingly, while the inhibitors alone had little impact on replication, they functioned
synergistically with IFN-β. When we investigated the point in the viral lifecycle affected, we
found that the levels of the IE proteins ICP0 and ICP4 were relatively unaltered, while there
was large decrease in both the E protein, UL42, and L protein, VP5. This result suggests that
the CK2 inhibitors impair the activity of an IE protein that functions to overcome the IFN
response. Of the HSV-1 IE proteins, both ICP0 and ICP27 have been identified as
antagonists of the IFN response. This study focused on whether inhibition of CK2 activity
influenced ICP0’s ability to counteract the IFN response. We were unable to examine the
role of ICP27 in this study as the loss of ICP27 is deleterious (Sacks et al., 1985) and, as is
discussed below, mutations of the CK2 phosphoacceptor sites of ICP27 significantly impair
HSV-1 replication (Rojas et al., 2010). Our results demonstrate that the CK2 inhibitors were
unable to increase the IFN sensitivity of an ICP0-null mutant, indicating a requirement for
CK2 inICP0’s anti-IFN activity. To determine if the combination of CK2 inhibitor and IFN-
β impede a key function of ICP0, we examined the ability of ICP0 to direct the degradation
of two of its targets, PML and DNA-PKcs, in cells treated with the CK2 inhibitors. In these
assays, we did not observe the inhibitors inducing a stabilization of either target. While ICP0
may be a CK2 substrate, it appears that phosphorylation of ICP0 by CK2 is not necessary for
its E3 ubiquitin ligase activity in our assays. It is possible that phosphorylation of ICP0 by
CK2 may affect an activity of ICP0 not linked to its E3 ligase activity in order to promote
efficient viral replication in the presence of IFN-β, or that ICP0 activates the expression of
an E and/or L gene and that the protein product of this viral gene is phosphorylated byCK2
to inactivate components in the IFN response. Regarding the former possibility, we have
previously shown in transient transfection assays that ICP0 mutated in two regions
containing potential CK2 phosphorylation sites exhibit defects in its transactivation activity
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(Davido et al., 2005); however, we have not tested the effects of these mutations during viral
infection in our assays.
We also noted in this study that the CK2 inhibitors alone do not appear to greatly impede the
replication of HSV-1, thus making CK2 activity likely dispensable for the growth of HSV-1.
This is unexpected given the number of HSV-1 proteins that have been identified as
potential CK2 substrates and that mutation of these CK2 phosphorylation sites is detrimental
to viral replication (Xia et al., 1996; Wisner et al., 2000; Potel and Elliott, 2005; Boutell et
al., 2008; Rojas et al., 2010). As one example, mutation of CK2 phosphorylation sites in the
IE protein, ICP27, impairs viral replication (Rojas et al., 2010). This mutation, however,
may prevent a large conformational shift in the N-terminus of ICP27 that appears to be
necessary for its functions (Corbin-Lickfett et al., 2010) and do so in a CK2
phosphorylation-independent manner. It is also probable that residual CK2 kinase activity
may remain after TBB or TMCB treatment or that the stimulation of CK2 activity by ICP27
(Koffa et al., 2003) is able to overcome the effect of the CK2 inhibitors; however, these
possibilities seem unlikely as a further reduction in plaque size or plating efficiency was not
observed when higher levels of either inhibitor were used (data not shown).
While the enhanced sensitivity of IFN induced by CK2 inhibitors requires at least one
HSV-1 protein, it is also plausible that this effect could be mediated by one more cellular
factors. To explore this possibility, we examined whether the CK2 inhibitors influenced the
IFN-sensitivity of two other viruses, VSV and Ad5. We found that the CK2 inhibitors used
alone affected neither virus. While IFN-β impaired the replication of VSV, neither inhibitor
increased this impairment beyond that of IFN-β alone. Ad5, on the other hand, was largely
impervious to the effect of IFN-β and the use of the CK2 inhibitors failed to change this.
Although the CK2 inhibitors alone did not alter VSV replication, it was recently reported
that use of the CK2 inhibitor, DMAT, or siRNA-mediated silencing of CK2 increased VSV
replication (Sun et al., 2011). Likewise, the CR2 region of the Ad5 E1A protein contains a
consensus CK2 phosphorylation motif (Whalen et al., 1996). In the case of VSV, the
discrepancy may lie in the cell lines used, as those studies were carried out in the highly
transformed HEK-293s. As for Ad5, while the CK2 site was implicated in binding to the
retinoblastoma protein and resistance to Ad-induced cell death, the role of phosphorylation
at this site in Ad5 replication is likely to be minimal as mutation of this site failed to affect
E1A transactivation activity (Whalen et al., 1996). In either case, the fact that the CK2
inhibitors did not increase the IFN-β sensitivity of VSV or Ad5 suggests that the CK2
inhibitors compromise an anti-IFN mechanism that is specific to HSV-1.
While we did not note either CK2 inhibitor having a large impact on the replication of either
VSV or Ad5, a number of other viruses have shown a dependence on CK2 activity for
efficient replication. For example, CK2 phosphorylation is involved in multiple steps of the
human immunodeficiency virus1 (HIV-1) lifecycle, including reverse transcription and gene
expression (Critchfield et al., 1997; Harada et al., 1999), and treatment with a CK2 inhibitor
has been reported to inhibit HIV-1 replication (Critchfield et al., 1997). Additionally, a CK2
inhibitor was recently shown to have antiviral activity towards varicella-zoster virus (Rowe
et al., 2010). It remains to be seen, however, if the enhancement by CK2 inhibitors on the
potency of IFN is restricted to HSV-1 or if this extends to other members of the herpesvirus
family or more broadly to other viral families. Nevertheless, CK2 inhibitors show promise
as anti-HSV-1 therapeutic agents when used in combination with other antiviral treatments.
Notably, the CK2 inhibitor, TBB, has been shown to be efficacious in limiting retinal
pathologies in mice (Ljubimov et al., 2004).
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7. Glossary
Ad5 adenovirus type 5
αMEM Minimum Essential Medium Eagle Alpha Modification
ANOVA Analysis of variance
CDK9 cyclin-dependent kinase 9
DMAT 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole
DMEM Dulbecco’s modified Eagle’s medium
DMSO dimethylsulfoxide
DNA-PKcs DNA-dependent protein kinase catalytic subunit
dpi days post infection
DRB 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole
E early
FBS fetal bovine serum
HEL human embryonic lung
HIV-1 human immunodeficiency virus 1
hpi hours post infection
HRP horseradish peroxidase
HSV-1 herpes simplex virus type 1
gE glycoprotein E
GFP green fluorescent protein
ICP0 infected cell protein 0
ICP4 infected cell protein 4
ICP6 infected cell protein 6




PFU plaque forming unit
PML promyelocytic leukemia protein
SEM standard error of the mean
siRNA small interfering RNA
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TBS-T tris buffered saline plus tween 20
TMCB 2-(4,5,6,7-tetrabromo-2-(dimethylamino)-1H-benzo[d]imidazol-1-yl)acetic
acid
VP1/2 viral protein 1/2
VP13/14 viral protein 13/14
VP16 viral protein 16
VP22 viral protein 22
VSV vesicular stomatitis virus
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The effect of IFN-β and CK2 inhibitors on viral replication. HEL cells were pretreated with
or without IFN-β for 16 h and subsequently infected with wild-type HSV-1, strain KOS, (A
& C) or an ICP0 null mutant, 7134, (B & D) at 1 PFU per cell in the presence of IFN-β,
DMSO (vehicle), TBB, or TMCB or a combination of IFN and DMSO, TBB, or TMCB. At
24 hpi, infected cells were harvested, and wild-type HSV-1was titered on Vero cells and the
ICP0 null mutanton L7 cells. The data shown in A and B are the mean titers (± SEM) of two
experiments performed in duplicate; C and D are the titers expressed as fold decrease
relative to untreated cells.
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The combination of CK2 inhibitor and IFN-β decreases early and late protein levels. HEL
cells were treated and infected as described in Figure 1. At 12 and 24 hpi, cells were washed
with PBS before being resuspended into loading buffer. Lysates were resolved by SDS-
PAGE and analyzed by western blot for ICP4, UL42, VP5, or β-actin expression. Band
intensities were measured by densitometry analyses using ImageJ. UL42 (ce):the UL42 24
hpi lanes contrast enhanced (ce) using Adobe Photoshop.
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CK2 inhibitors do not prevent the loss of PML and DNA-PKcs staining mediated by ICP0.
HEL cells were treated and infected as described in Figure 1. At 12 hpi, cells were fixed and
stained with antibodies against DNA-PKcs, PML, and ICP0. PML is shown as blue, DNA-
PKcs as red, and ICP0 as green in the merged image. The yellow, orange, and red arrows
indicate a cell that stains positive for ICP0 (red arrow) but has reduced or no apparent
staining for PML (yellow arrow) and DNA-PKcs (orange arrow).
Smith et al. Page 15














CK2 inhibitors do not stabilize PML levels during infection. HEL cells were treated, as
described in Figure 1, infected with wild-type HSV-1, and harvested at 12 and 24 hpi. Cell
lysates were analyzed for PML, ICP0, or β-actin expression by western blot analyses.
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TABLE 1
Plaque size and plating efficiency of HSV-1 in CK2 inhibitor-, IFN-β-, or IFN-β plus CK2 inhibitor-treated
cells.
Treatment Area (mm2)a Area (fold change)b Area (fold decrease vs IFN-β)c
Plating efficiency (fold
decrease)d
None 5.470 (± 0.564) – – –
DMSO 4.670 (± 0.644) ↓1.2 – 1
TBB 1.410 (± 0.193) ↓3.9 – 1
TMCB 3.830 (± 0.414) ↓1.4 – ↓2
50 U/mL IFN-β 1.160 (± 0.126) ↓4.7 – ↓4
50 U/mL IFN-β + DMSO 0.970 (± 0.106) ↓5.6 ↓1.2 ↓4
50 U/mL IFN-β + TBB 0.130 (± 0.011) ↓42.1 ↓8.9* ↓9
50 U/mL IFN-β + TMCB 0.530 (± 0.065) ↓10.3 ↓2.2* ↓7
1000 U/mL IFN-β 0.210 (± 0.025) ↓26.0 – ↓25
1000 U/mL IFN-β + DMSO 0.120 (± 0.011) ↓45.6 ↓1.8* ↓27
1000 U/mL IFN-β + TBB 0.060 (± 0.005) ↓91.2 ↓3.5* ↓71
1000 U/mL IFN-β + TMCB 0.080 (± 0.007) ↓68.4 ↓2.6* ↓52
a
Plaque areas were determined by capturing images of immunohistochemically stained plates with a flatbed scanner and measuring the number of
pixels that corresponded to an individual plaque in Adobe Photoshop. The pixel values were converted to mm2 by dividing that value by the
number of pixels per inch for the image. Four to twenty plaques were measured per treatment for two experiments, and the results for one
experiment are shown above. Data are shown as the means (± SEM).
b
Fold change relative to untreated cells (“None”).
c
One way ANOVA (P < 0.05), Bonferroni’s multiple comparison post-test (*, P < 0.05) compared to the IFN-treated group
d
Plating efficiency decrease was calculated by dividing the number of plaques in the untreated sample by the number of plaques for a given
treatment. The data shown are the means of two experiments.
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TABLE 2
Plating efficiency of VSV and Ad5 in CK2 inhibitor-, IFN-β-, or IFN-β plus CK2 inhibitor-treated cells.






IFN-β + DMSO ↓74
IFN-β + TBB ↓66






IFN-β + DMSO ↓3
IFN-β + TBB ↓5
IFN-β + TMCB ↓4
a
Plating efficiency decrease was calculated by dividing the number of plaques in the untreated sample by the number of plaques for a given
treatment. The data shown are the means of two experiments.
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